Identification of an autophagy-related gene signature that can improve prognosis of hepatocellular carcinoma patients

BMC Cancer. 2020 Aug 17;20(1):771. doi: 10.1186/s12885-020-07277-3.

Abstract

Background: Autophagy is a programmed cell degradation mechanism that has been associated with several physiological and pathophysiological processes, including malignancy. Improper induction of autophagy has been proposed to play a pivotal role in the progression of hepatocellular carcinoma (HCC).

Methods: Univariate Cox regression analysis of overall survival (OS) was performed to identify risk-associated autophagy-related genes (ARGs) in HCC data set from The Cancer Genome Atlas (TCGA). Multivariate cox regression was then performed to develop a risk prediction model for the prognosis of 370 HCC patients. The multi-target receiver operating characteristic (ROC) curve was used to determine the model's accuracy. Besides, the relationship between drug sensitivity and ARGs expression was also examined.

Results: A total of 62 differentially expressed ARGs were identified in HCC patients. Univariate and multivariate regression identified five risk-associated ARGs (HDAC1, RHEB, ATIC, SPNS1 and SQSTM1) that were correlated with OS in HCC patients. Of importance, the risk-associated ARGs were independent risk factors in the multivariate risk model including clinical parameters such as malignant stage (HR = 1.433, 95% CI = 1.293-1.589, P < 0.001). In addition, the area under curve for the prognostic risk model was 0.747, which indicates the high accuracy of the model in prediction of HCC outcomes. Interestingly, the risk-associated ARGs were also correlated with drug sensitivity in HCC cell lines.

Conclusion: We developed a novel prognostic risk model by integrating the molecular signature and clinical parameters of HCC, which can effectively predict the outcomes of HCC patients.

Keywords: Autophagy; Autophagy-related genes; Drug sensitivity; HCC; Molecular signature.

MeSH terms

  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Autophagy / genetics*
  • Biomarkers, Tumor / genetics*
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / mortality*
  • Carcinoma, Hepatocellular / therapy
  • Cell Line, Tumor
  • Datasets as Topic
  • Disease Progression
  • Disease-Free Survival
  • Drug Resistance, Neoplasm / genetics
  • Female
  • Gene Expression Regulation, Neoplastic
  • Hepatectomy
  • Humans
  • Inhibitory Concentration 50
  • Kaplan-Meier Estimate
  • Liver / pathology
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / genetics
  • Liver Neoplasms / mortality*
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Models, Statistical*
  • Neoplasm Staging
  • Prognosis
  • RNA-Seq
  • ROC Curve
  • Risk Assessment / methods
  • Risk Factors

Substances

  • Antineoplastic Agents
  • Biomarkers, Tumor